A class action lawsuit has been filed against Aquestive Therapeutics and certain officers for alleged securities fraud. The complaint alleges that defendants made materially false statements regarding the timeline for FDA approval of Anaphylm and concealed significant human factors risks associated with the sublingual film product that could impact regulatory approval.

A class action lawsuit has been filed against Gossamer Bio, Inc. alleging that the company made materially false and misleading statements regarding its Phase 3 PROSERA study results while concealing material adverse facts about the study design, particularly regarding placebo response control at Latin American testing sites. The lawsuit covers investors who purchased Gossamer securities between June 16, 2025 and February 20, 2026. The lead plaintiff deadline is June 1, 2026.

Levi & Korsinsky has filed securities fraud lawsuits against three companies for allegedly misleading investors. Coty Inc. is accused of issuing overly optimistic guidance in November 2025 before reversing course in February 2026, resulting in a 22% stock decline. Power Solutions International and Gossamer Bio face similar allegations of concealing material deterioration and clinical execution failures, respectively. Investors with losses during the class action periods may seek damages.

Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Gossamer Bio, Inc. for alleged securities fraud. The company failed to disclose that Latin American trial sites enrolled heavily-treated, lower-risk patients who performed well on placebo, causing the Phase 3 PROSERA study to miss its primary endpoint. Gossamer's stock plummeted 80.3% on February 23, 2026, following the disclosure. The deadline to file a lead plaintiff motion is June 1, 2026.

The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.

Law firm Holzer & Holzer, LLC announced shareholder class action lawsuits against New Era Energy & Digital, Inc. (NUAI) and Gossamer Bio, Inc. (GOSS) for allegedly making materially false statements. NUAI is accused of misrepresenting progress on its Texas Critical Data Centers project between November 2024 and December 2025, while GOSS faces allegations regarding its Phase 3 PROSERA study between June 2025 and February 2026. The deadline to seek lead plaintiff status is June 1, 2026.

A securities class action lawsuit has been filed against Gossamer Bio, Inc. for allegedly providing misleading statements about its Phase 3 PROSERA study for pulmonary arterial hypertension treatment. The study failed to meet its primary endpoint, causing the stock to plummet over 80% from $2.13 to $0.42 per share on February 23, 2026. Investors who purchased shares between June 16, 2025, and February 20, 2026, are eligible to participate in the class action.

XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.

Pomerantz LLP announced investigations into potential securities fraud at Gossamer Bio, The Chemours Company, and Alight, Inc. on behalf of investors. The investigation was triggered by Gossamer Bio's failed Phase 3 trial for seralutinib, which caused its stock to plummet 80.14% on February 23, 2026.

Respira Therapeutics has granted Gossamer Bio an option to acquire the company, focusing on developing RT234, an investigational as-needed treatment for pulmonary hypertension. The agreement includes stock issuance and potential milestone payments.

Gossamer Bio has entered an option agreement to acquire Respira Therapeutics and its lead candidate RT234, an inhaled vardenafil therapy for pulmonary hypertension, with potential to expand its pulmonary hypertension treatment portfolio.

The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is expected to grow significantly between 2025-2034, driven by improved diagnostic techniques, disease recognition, and emerging therapies targeting functional improvement and disease progression.